Treatment of Ph-Like Acute Lymphoblastic Leukemia

Tran, Thai Hoa; Tasian, Sarah K.

doi:10.1007/978-3-030-85147-7_10

Cited by 1 publication

(1 citation statement)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poor outcome was reported in ALL patients above 15 years old, who were MRD positive after the initial therapy and receive no blinatumomab before allogeneic HSCT, which was confirmed in a large European retrospective analysis [ 89 ]. Despite that the previous trials did not screen for Ph-like ALL, it is assumed that blinatumomab could have similar efficacy in Ph-like ALL [ 90 ].…”

Section: Role Of Hematopoietic Stem Cell Transplantation Based On Mrd...mentioning

confidence: 99%

Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant—review article

2023

View full text Add to dashboard Cite

Philadelphia chromosome-like (Ph-like) ALL is a recent subtype of acute lymphoblastic leukemia. Although it does not express the BCR-ABL fusion gene, it has a behavior like true BCR/ABL1–positive cases. This subtype harbors different molecular alterations most commonly CRLF2 rearrangements. Most cases of Ph-like ALL are associated with high white blood cell count, high minimal residual disease level after induction therapy, and high relapse rate. Efforts should be encouraged for early recognition of Ph-like ALL to enhance therapeutic strategies. Recently, many trials are investigating the possibility of adding the tyrosine kinase inhibitor (TKI) to chemotherapy to improve clinical outcomes. The role and best timing of allogeneic bone marrow transplant in those cases are still unclear. Precision medicine should be implemented in the treatment of such cases. Here in this review, we summarize the available data on Ph-like ALL

show abstract

Section: Role Of Hematopoietic Stem Cell Transplantation Based On Mrd...mentioning

confidence: 99%